Physician profile
Alan Grosset
NPI 1689667263
$3,895.34
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $1,882 · 2021: $155 · 2022: $594 · 2023: $290 · 2024: $273 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.07 |
| Education | $318.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,763.17 | 2020-2023 | |
| Daiichi Sankyo INC. | $579.55 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $307.84 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Inari Medical, INC. | $189.83 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Seagen INC. | $164.98 | 2025 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2019 | |
| Akcea Therapeutics, INC. | $125.00 | 2020 | |
| Dova Pharmaceuticals | $114.42 | 2021 | |
| Pfizer INC. | $67.10 | 2025 | |
| Tersera Therapeutics LLC | $62.86 | 2024-2025 | Zoladex |
| Genentech, INC. | $53.45 | 2023 | Hemlibra |
| Emd Serono, INC. | $43.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.06 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.18 | 2025 | Iclusig |
| Astellas Pharma US INC | $31.42 | 2025 | Vyloy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $28.59 | 2025 | Mektovi, Xalkori, Lorbrena |
| Amgen INC. | $28.54 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.69 | 2025 | |
| Aadi Bioscience, INC. | $22.56 | 2023 | Fyarro |
| Genentech USA, INC. | $22.13 | 2023 | Columvi, Polivy |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.21 | 2025 | |
| Lilly USA, LLC | $15.54 | 2024 | Jaypirca, Retevmo, Verzenio |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Grosset listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.